Celgene’s Revlimid Wins Expanded Use for Blood Cancer

Celgene Corp.’s Revlimid, the company’s best-selling drug, won approval for wider use in patients with a rare and aggressive form of cancer called mantle cell lymphoma that starts in white blood cells.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.